Sorry - not buying it. The market cap is 10 million, yet the "services business" is barely cash positive. They have 3 million in cash, but most of that will be burned on the Phase I trials. Their valuation is pretty high considering that most drugs fail Phase I, and very high considering that this drug is targeting a small, specialty market.
Right now, 10 -12 cents seems fairer value.
- Forums
- ASX - By Stock
- NDL
- research
research , page-16
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NDL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online